MGMT and glioblastoma: In children with HGG current clinical trials evaluate the therapeutic benefit of temozolomide treatment and the role of prognostic factors defined in adult GBM such as 1p19q status, isocitrate dehydrogenase (IDH) mutation status, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status [6].